See more : Bhageria Industries Limited (BHAGERIA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of MannKind Corporation (MNKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MannKind Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fletcher Building Limited (FBU.NZ) Income Statement Analysis – Financial Results
- Nippon Sharyo, Ltd. (7102.T) Income Statement Analysis – Financial Results
- Lynx Global Digital Finance Corporation (LYNX.CN) Income Statement Analysis – Financial Results
- CVR Partners, LP (UAN) Income Statement Analysis – Financial Results
- Dai Nippon Printing Co., Ltd. (7912.T) Income Statement Analysis – Financial Results
MannKind Corporation (MNKD)
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.75M | 174.76M | 0.00 | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Cost of Revenue | 62.77M | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M | 17.23M | 50.09M | 140.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 136.19M | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M | -5.48M | 124.67M | -140.41M | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Gross Profit Ratio | 68.45% | 42.37% | 48.49% | 62.17% | 55.62% | 26.49% | -46.68% | 71.34% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 31.28M | 19.72M | 12.31M | 6.25M | 6.90M | 8.74M | 14.12M | 14.92M | 29.67M | 100.24M | 109.72M | 101.52M | 99.96M | 112.28M | 156.33M | 250.44M | 256.84M | 191.80M | 95.35M | 59.27M | 45.61M | 42.72M | 19.76M | 20.54M |
| General & Administrative | 42.54M | 37.72M | 31.89M | 22.88M | 0.00 | 79.72M | 74.96M | 27.07M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 51.78M | 53.75M | 45.53M | 34.37M | 0.00 | 0.00 | 0.00 | 19.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 94.31M | 91.47M | 77.42M | 59.04M | 74.67M | 79.72M | 74.96M | 46.93M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 20.70M | 13.22M | 0.00 | 4.85M |
| Other Expenses | 1.92M | -102.00K | 339.00K | 23.00K | -926.00K | -437.00K | 13.00K | -597.00K | 1.37M | 1.68M | -635.00K | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.60M | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M | 88.86M | 59.58M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Cost & Expenses | 190.28M | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M | 106.09M | 109.67M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Interest Income | 6.15M | 2.51M | 112.00K | 167.00K | 997.00K | 501.00K | 293.00K | 85.00K | 18.00K | 9.00K | 8.00K | 7.00K | 18.00K | 40.00K | 70.00K | 5.13M | 17.78M | 0.00 | 3.71M | 932.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.16M | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M | 13.28M | 18.48M | 24.13M | 20.44M | 21.46M | 21.63M | 21.82M | 17.38M | 10.45M | 2.34M | 3.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.54M | 6.29M | 3.26M | 2.98M | 2.78M | 1.70M | 1.80M | 2.40M | 13.28M | 18.58M | 14.06M | 14.40M | 15.91M | 17.32M | 18.73M | 12.29M | 8.97M | 8.52M | 7.39M | 7.18M | 7.66M | 5.07M | 50.08M | -204.00K |
| EBITDA | 15.13M | -56.34M | -61.09M | -45.01M | -38.22M | -75.60M | -102.21M | 146.54M | -344.66M | -160.18M | -155.97M | -133.74M | -123.68M | -135.86M | -190.93M | -288.41M | -280.81M | -225.18M | -106.95M | -68.81M | -58.63M | -51.35M | 289.00K | -25.45M |
| EBITDA Ratio | 7.60% | -66.66% | -71.06% | -37.75% | -73.67% | -280.49% | -800.67% | 36.95% | 0.00% | 0.00% | 0.00% | -423,268.57% | -281,042.00% | -163,196.77% | 0.00% | -1,503,180.00% | -2,981,870.00% | -225,388.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.65% | -16,523.38% |
| Operating Income | 8.68M | -68.92M | -53.48M | -24.79M | -46.51M | -76.60M | -108.19M | 67.26M | -344.66M | -179.63M | -169.40M | -146.96M | -140.54M | -152.50M | -209.78M | -305.77M | -307.36M | -233.70M | -118.12M | -77.15M | -66.31M | -207.37M | -49.79M | -25.24M |
| Operating Income Ratio | 4.36% | -69.08% | -70.89% | -38.05% | -73.78% | -274.94% | -921.15% | 38.49% | 0.00% | 0.00% | 0.00% | -419,885.71% | -281,078.00% | -163,976.34% | 0.00% | -1,528,825.00% | -3,073,570.00% | -233,697.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,273.62% | -16,390.91% |
| Total Other Income/Expenses | -19.06M | -23.29M | -33.90M | -9.55M | -7.31M | -10.14M | -9.09M | 58.40M | -23.79M | -18.76M | -22.09M | -22.81M | -20.27M | -18.06M | -10.33M | 2.73M | 14.17M | 3.15M | 3.79M | 1.16M | 434.00K | 1.10M | 1.55M | 583.00K |
| Income Before Tax | -10.38M | -87.40M | -80.93M | -57.46M | -51.90M | -86.74M | -117.28M | 125.66M | -368.45M | -198.38M | -191.49M | -169.77M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.54M | -114.34M | -75.99M | -65.88M | -206.26M | -48.24M | -24.66M |
| Income Before Tax Ratio | -5.22% | -87.60% | -107.27% | -88.20% | -82.34% | -311.34% | -998.57% | 71.91% | 0.00% | 0.00% | 0.00% | -485,068.57% | -321,608.00% | -183,397.85% | 0.00% | -1,515,185.00% | -2,931,870.00% | -230,543.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,798.47% | -16,012.34% |
| Income Tax Expense | 1.56M | 24.77M | 10.87M | -218.00K | 7.83M | 240.00K | 51.00K | 13.72M | 12.22M | 3.55M | 6.77M | -408.00K | 5.91M | 738.00K | -8.28M | 2.00K | 3.00K | 5.00K | 1.00K | 1.00K | 1.00K | 2.00K | 2.00K | 2.00K |
| Net Income | -11.94M | -112.17M | -91.79M | -57.24M | -59.73M | -86.98M | -117.33M | 125.66M | -368.45M | -198.38M | -191.49M | -169.37M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.55M | -114.34M | -75.99M | -65.88M | -206.27M | -48.25M | -24.66M |
| Net Income Ratio | -6.00% | -112.43% | -121.67% | -87.87% | -94.75% | -312.20% | -999.00% | 71.91% | 0.00% | 0.00% | 0.00% | -483,902.86% | -321,608.00% | -183,397.85% | 0.00% | -1,515,195.00% | -2,931,900.00% | -230,548.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,799.08% | -16,013.64% |
| EPS | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| EPS Diluted | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| Weighted Avg Shares Out | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 103.83M | 92.05M | 81.16M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
| Weighted Avg Shares Out (Dil) | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 104.25M | 92.09M | 81.23M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
Rapidly enrolled 141 patients in less than four months Large study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (insulin human) Inhalation Powder) Initial standardized meal...
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss...
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
DANBURY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced a new patent (No....
Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)
Tyvaso DPI, a collaboration with United Therapeutics, diversifies MannKind's revenue streams and leverages its proprietary Technosphere technology, bolstering long-term prospects. While Afrezza faces challenges like pricing and reimbursement, MNKD's efforts to improve market penetration suggest a proactive strategy to turn...
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today...
3 Biotech Stocks to Sell in August Before They Crash and Burn
Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of...
Why MannKind Stock Soared 19% Higher on Tuesday
There's nothing like an estimate-topping quarter to put some pep in a company. A big jump in royalty revenue was particularly notable.
MannKind Corporation (MNKD) Q2 2023 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Company Olivia Brayer...
Here's What Key Metrics Tell Us About MannKind (MNKD) Q2 Earnings
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
MannKind (MNKD) Reports Break-Even Earnings for Q2
MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.11 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports